The global thrombopoietin receptor agonists market focuses on the manufacturing, marketing, and development of thrombopoietin receptor agonists (TPO-RAs) in oral or injectable formulations. TPO-RAs are employed for the treatment of thrombocytopenia and in the prevention or treatment of bleeding.
The H2 is constituting due to the rising incidence of thrombocytopenia, the growing need for targeted treatment, as well as due to the expansion of the number of new TPO-RA approvals. The rising demand for healthcare services due to the aging population, rising incidence of chronic and infectious diseases, and development of new markets. Medical devices appear to be an important sector in the global markets of health systems. North America remained the largest market for thrombopoietin receptor agonists market in 2023 backed by recent advancements in the healthcare sector and R&D initiatives in this region. Determined countries are the U.S. and Canada because there is increasing concern about chronic liver disease and cancer. The expected incidence of acute myeloid leukemia by 2024 is 20,800 in the United States of America while total mortality is expected to be 11,220.
Download
Order Databook
Actionable Solutions
